Who Paid My Doc
Hepatic Impairment
Research payments
$5,868,715
Through program year 2025, $5,868,715 in research payments was reported against Hepatic Impairment, across 268 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Celgene Corporation and 3 more
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $291,456 | 72 |
| 2024 | Research | $830,970 | 103 |
| 2023 | Research | $691,647 | 42 |
| 2022 | Research | $380,671 | 13 |
| 2021 | Research | $287,865 | 11 |
| 2020 | Research | $2,102,972 | 14 |
| 2019 | Research | $1,283,132 | 13 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rohit Loomba La Jolla, CA Named on 46 payments
- Paul Kwo Stanford, CA Named on 26 payments
- Charlton Strange Charleston, SC Named on 22 payments
- Eric Lawitz San Antonio, TX Named on 16 payments
- Virginia Clark Gainesville, FL Named on 13 payments
- Meagan Gray Birmingham, AL Named on 12 payments
- Robert Fontana Ann Arbor, MI Named on 12 payments
- Antonio Sanchez Iowa City, IA Named on 9 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.